⌘K
Loading ticker…
Cullinan Therapeutics, Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, Cullinan Therapeutics, Inc. Common Stock (CGEM) has a 3-month relative strength percentile of 84 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 79. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 9.1%, relative volume 1.88×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
3m RS is 84, Market Stance is mixed at 47, A/D rating C
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
CGEM is in a stage 2 uptrend, week 2. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 24.7% / 57.4%.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
CGEM is held by 5 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $26M notional. Top 3 carry $64M.
Top 5 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $26M |
| IWMiShares Russell 2000 ETF | 0.03% | $19M |
| XBIState Street SPDR S&P Biotech ETF | 0.25% | $19M |
| VXFVanguard Extended Market ETF | 0.01% | $8M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $1M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CGEM Jan avg: 15.29% median: 12.94% win: 75% σ: 25.50% n: 4 2022-04-12 → 2026-05-29 | CGEM Feb avg: 7.25% median: 9.49% win: 50% σ: 22.68% n: 4 2022-04-12 → 2026-05-29 | CGEM Mar avg: -9.07% median: -8.86% win: 0% σ: 1.36% n: 4 2022-04-12 → 2026-05-29 | CGEM Apr avg: 8.67% median: -4.89% win: 40% σ: 28.97% n: 5 2022-04-12 → 2026-05-29 | CGEM May avg: 6.40% median: 5.65% win: 80% σ: 13.88% n: 5 2022-04-12 → 2026-05-29 | CGEM Jun avg: -3.52% median: -4.11% win: 50% σ: 20.00% n: 4 2022-04-12 → 2026-05-29 (current) | CGEM Jul avg: 4.49% median: 4.29% win: 75% σ: 5.20% n: 4 2022-04-12 → 2026-05-29 | CGEM Aug avg: -1.04% median: -1.24% win: 25% σ: 1.94% n: 4 2022-04-12 → 2026-05-29 | CGEM Sep avg: -13.35% median: -13.58% win: 0% σ: 6.77% n: 4 2022-04-12 → 2026-05-29 | CGEM Oct avg: 11.13% median: 2.79% win: 75% σ: 23.74% n: 4 2022-04-12 → 2026-05-29 | CGEM Nov avg: 0.04% median: -8.81% win: 25% σ: 21.14% n: 4 2022-04-12 → 2026-05-29 | CGEM Dec avg: -2.28% median: -9.21% win: 25% σ: 18.02% n: 4 2022-04-12 → 2026-05-29 |